Abstract Library

#4649 Claudin 18.2 overexpression in gastric neuroendocrine tumours

Introduction: Claudin 18.2, is a tissue biomarker physiologically expressed in both healthy gastric mucosa and gastric adenocarcinoma which represents a novel therapeutic target advanced gastric cancer. Various other cancers showed some overexpression of claudin 18.2 opening potential opportunities to agnostic targeted therapy. However, data about claudin 18.2 expression in NENs are poor with only an Eastern study showing higher rate of claudin 18.2 positivity in GEP-NENs, mainly from gastric primary site (27.8%).

Conference:

Presenting Author: Gervaso L

Authors: Gervaso L, Lobrano R, Pisa E, Benini L, Spada F,

Keywords: claudin, gastric NET, biomarker, Neuroendocrine tumour,

#4526 The relationship between adherence to traditional Chinese medicine and disease progression in type 1 gastric neuroendocrine tumours: A case report

Introduction: Type 1 gastric neuroendocrine tumours (g-NETs) have a high recurrence risk after endoscopic resection, underscoring the need for regular endoscopic follow-up. Our research hints that Traditional Chinese Medicine (TCM) could help lower recurrence rates.

Conference:

Presenting Author: Wang Y

Authors: Wang Y, Cheng Z, Yu F, Chen R, Chen X,

Keywords: type 1 gastric neuroendocrine tumour, Traditional Chinese Medicine, regular follow-up, case report,

#3737 The use of somatostatin analogues in a pregnant patient with gastric NET

Introduction: The question of the use of somatostatin analogues (ASS) during pregnancy remains open and requires further clarifications and observations, but based on the facts already known to us, we can suggest that, despite the fact that there are currently no adequate well-designed and well-controlled studies evaluating the use of ASS in pregnant women, there is enough data on a limited number of patients indicating on the absence of undesirable effects of ASS on the course of pregnancy or the health of the fetus/newborn.

Conference:

Presenting Author: Androsova A

Authors: Androsova A, Orlova R, Ivanova A, Belyak N, Kutukova S,

Keywords: somatostatin analogues, Pregnancy, Neuroendocrine tumor,

#3417 SARS-CoV-2 vaccination site as possible pitfall on somatostatin receptor imaging

Introduction: SARS-CoV-2 (COVID19) vaccinations have shown high efficacy. Therefore, increased chances exist that patients undergoing Peptide Receptor Radionuclide Therapy (PRRT) or radionuclide imaging for Neuroendocrine Tumors (NETs) may have being recently vaccinated.

Conference:

Presenting Author: Kolade O

Authors: Kolade O, Ayeni A, Brink A, Steyn R, Prasad V,

Keywords: COVID-19, SARS-CoV-2, Lu-177 DOTATATE, Ga-68 DOTANOC, Vaccination, PRRT, Neuroendocrine Tumor,

#3293 Clinicopathological features and risk analysis of lymph node metastasis in type 3 gastric neuroendocrine tumor

Introduction: Type 3 gastric neuroendocrine tumor (NET) are a rare tumor and its high-risk factors of lymph node metastasis remain unclear.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Li Y, Tan H,

Keywords: type 3 gastric neuroendocrine tumor, clinicopathological features, lymph node metastases,